Population perspectives on benefits and harms of screening for metabolic dysfunction-associated steatotic liver disease. Allen AM, Kim WR, Carrieri P, Canning R, et al. Hepatology 2026;83:362-373.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Allen AM, Kim WR, Carrieri P, Canning R, et al. Population perspectives on benefits and harms of screening for metabolic dysfunction-associated steatotic liver disease. Hepatology 2026;83:362-373.
PMID: 40105977